LYBALVI
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $6.4M | 17,479 | 7,491 |
| 2023 | $7.2M | 21,872 | 8,544 |
| 2022 | $7.7M | 24,361 | 8,797 |
| 2021 | $2.0M | 5,377 | 3,353 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14.0M | 5,878 | 60.1% |
| Unspecified | $4.3M | 1,476 | 18.4% |
| Food and Beverage | $2.6M | 53,220 | 11.0% |
| Travel and Lodging | $1.9M | 7,461 | 8.2% |
| Consulting Fee | $516,495 | 125 | 2.2% |
| Education | $7,429 | 929 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder | Alkermes, Inc. | $1.5M | 0 |
| A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) | Alkermes, Inc. | $1.3M | 0 |
| Long-term, safety extension study of OLZ/SAM in pediatric subjects with schizophrenia or bipolar I disorder (ENLIGHTEN Youth Extension) | Alkermes, Inc. | $472,671 | 0 |
| Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | Alkermes, Inc. | $437,301 | 0 |
| A Phase 1, Multiple-dose, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OLZ/SAM in Pediatric Subjects (10-12 Years Old) With Bipolar I Disorder | Alkermes, Inc. | $322,298 | 0 |
| Long-term, safety extension study of OLZ/SAM in pediatric subjects withschizophrenia or bipolar I disorder (ENLIGHTEN Youth Extension) | Alkermes, Inc. | $292,710 | 0 |
Top Doctors Receiving Payments for LYBALVI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | St. Louis, MO | $4.3M | 1,493 |
| , DNP | Family | Orlando, FL | $361,313 | 599 |
| , MD, MPH | Psychiatry | Suffern, NY | $331,357 | 316 |
| , MD | Psychiatry | Austin, TX | $295,727 | 251 |
| , MD | Psychiatry | Columbus, OH | $279,720 | 334 |
| , M.D | Psychiatry | Clifton, NJ | $253,151 | 356 |
| , MD | Psychiatry | Orange, CA | $251,862 | 238 |
| , MD | Psychiatry | University Park, FL | $248,220 | 247 |
| , M.D., PH.D | Psychiatry | Detroit, MI | $242,299 | 190 |
| , M.D | Psychiatry | Bloomfield Hills, MI | $237,965 | 212 |
| , ARNP | Psychiatric/Mental Health | Atlantic, IA | $233,665 | 391 |
| , M.D | Psychiatry | Los Gatos, CA | $224,984 | 281 |
| , MD | Psychiatry | Fort Wayne, IN | $222,998 | 251 |
| , MD | Psychiatry | Pittsburgh, PA | $220,425 | 313 |
| , M.D | Internal Medicine | Hickory, NC | $215,900 | 240 |
| , M.D | Psychiatry | Nashville, TN | $209,411 | 282 |
| , MD | Psychiatry | Los Angeles, CA | $208,624 | 330 |
| , MD, MPH | Psychiatry | Birmingham, AL | $200,148 | 207 |
| , M.D | Psychiatry | Katy, TX | $198,203 | 277 |
| , M.D | Psychiatry | Plano, TX | $195,366 | 256 |
| , MD | Psychiatry | Manassas, VA | $191,272 | 274 |
| , MD | Psychiatry | Monsey, NY | $189,407 | 148 |
| , MD | Psychiatry | Brookhaven, GA | $184,009 | 224 |
| , MD | Psychiatry | Atlanta, GA | $180,668 | 183 |
| , M.D | Psychiatry | San Diego, CA | $176,462 | 173 |
Manufacturing Companies
- Alkermes, Inc. $23.4M
Product Information
- Type Drug
- Total Payments $23.4M
- Total Doctors 18,295
- Transactions 69,089
About LYBALVI
LYBALVI is a drug associated with $23.4M in payments to 18,295 healthcare providers, recorded across 69,089 transactions in the CMS Open Payments database. The primary manufacturer is Alkermes, Inc..
Payment data is available from 2021 to 2024. In 2024, $6.4M was paid across 17,479 transactions to 7,491 doctors.
The most common payment nature for LYBALVI is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($14.0M, 60.1% of total).
LYBALVI is associated with 6 research studies, including "A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder" ($1.5M).